157 related articles for article (PubMed ID: 32733069)
1. Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.
Ge M; Li D; Qiao Z; Sun Y; Kang T; Zhu S; Wang S; Xiao H; Zhao C; Shen S; Xu Z; Liu H
Oncogene; 2020 Sep; 39(36):5888-5901. PubMed ID: 32733069
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Liu H; Westergard TD; Cashen A; Piwnica-Worms DR; Kunkle L; Vij R; Pham CG; DiPersio J; Cheng EH; Hsieh JJ
Cancer Cell; 2014 Apr; 25(4):530-42. PubMed ID: 24735925
[TBL] [Abstract][Full Text] [Related]
3. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
Ahmad K; Scholz B; Capelo R; Schweighöfer I; Kahnt AS; Marschalek R; Steinhilber D
Oncotarget; 2015 Sep; 6(28):25784-800. PubMed ID: 26329759
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
Ge M; Xu Q; Kang T; Li D; Wang R; Chen Z; Xie S; Wang W; Liu H
Cancer Sci; 2021 Jun; 112(6):2287-2298. PubMed ID: 33738896
[TBL] [Abstract][Full Text] [Related]
5. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
6. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
Xia ZB; Popovic R; Chen J; Theisler C; Stuart T; Santillan DA; Erfurth F; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):14028-33. PubMed ID: 16169901
[TBL] [Abstract][Full Text] [Related]
7. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
8. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
[TBL] [Abstract][Full Text] [Related]
9. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.
Thomas M; Gessner A; Vornlocher HP; Hadwiger P; Greil J; Heidenreich O
Blood; 2005 Nov; 106(10):3559-66. PubMed ID: 16046533
[TBL] [Abstract][Full Text] [Related]
10. Rationale for targeting BCL6 in
Hurtz C; Chan LN; Geng H; Ballabio E; Xiao G; Deb G; Khoury H; Chen CW; Armstrong SA; Chen J; Ernst P; Melnick A; Milne T; Müschen M
Genes Dev; 2019 Sep; 33(17-18):1265-1279. PubMed ID: 31395741
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by
Chu SH; Song EJ; Chabon JR; Minehart J; Matovina CN; Makofske JL; Frank ES; Ross K; Koche RP; Feng Z; Xu H; Krivtsov A; Nussenzweig A; Armstrong SA
Blood Adv; 2018 Oct; 2(19):2478-2490. PubMed ID: 30266823
[TBL] [Abstract][Full Text] [Related]
12. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
13. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
15. The reciprocal world of MLL fusions: A personal view.
Marschalek R
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194547. PubMed ID: 32294539
[TBL] [Abstract][Full Text] [Related]
16. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
17. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
18. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.
Liu H; Cheng EH; Hsieh JJ
Genes Dev; 2007 Oct; 21(19):2385-98. PubMed ID: 17908926
[TBL] [Abstract][Full Text] [Related]
19. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia.
Matkar S; Katona BW; Hua X
Cancer Cell; 2014 Apr; 25(4):411-3. PubMed ID: 24735921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
